- Home
- WHF vs CLYM Comparison
WHF vs CLYM Comparison
Compare WHF & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- CLYM
- Stock Information
- Founded
- WHF 2011
- CLYM 2018
- Country
- WHF United States
- CLYM United States
- Employees
- WHF N/A
- CLYM N/A
- Industry
- WHF Finance Companies
- CLYM
- Sector
- WHF Finance
- CLYM
- Exchange
- WHF Nasdaq
- CLYM NYSE
- Market Cap
- WHF 212.0M
- CLYM 86.5M
- IPO Year
- WHF 2012
- CLYM 2021
- Fundamental
- Price
- WHF $8.74
- CLYM $1.22
- Analyst Decision
- WHF Sell
- CLYM Buy
- Analyst Count
- WHF 4
- CLYM 1
- Target Price
- WHF $10.83
- CLYM $10.00
- AVG Volume (30 Days)
- WHF 106.0K
- CLYM 400.5K
- Earning Date
- WHF 08-07-2025
- CLYM 08-13-2025
- Dividend Yield
- WHF 20.40%
- CLYM N/A
- EPS Growth
- WHF N/A
- CLYM N/A
- EPS
- WHF 0.39
- CLYM N/A
- Revenue
- WHF $86,143,000.00
- CLYM N/A
- Revenue This Year
- WHF N/A
- CLYM N/A
- Revenue Next Year
- WHF N/A
- CLYM N/A
- P/E Ratio
- WHF $22.24
- CLYM N/A
- Revenue Growth
- WHF N/A
- CLYM N/A
- 52 Week Low
- WHF $8.44
- CLYM $1.05
- 52 Week High
- WHF $12.73
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- WHF 39.48
- CLYM N/A
- Support Level
- WHF $8.62
- CLYM N/A
- Resistance Level
- WHF $8.88
- CLYM N/A
- Average True Range (ATR)
- WHF 0.16
- CLYM 0.00
- MACD
- WHF -0.04
- CLYM 0.00
- Stochastic Oscillator
- WHF 11.54
- CLYM 0.00
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.